Citations (105)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (12)
Farah Raheem, Nada Alsuhebany, Erin Hickey Zacholski, Nikola Paulic, Anna Sandler, Nathan Uk & Donald C. Moore. (2023) Ocular toxicities associated with antibody drug conjugates and immunotherapy in oncology: clinical presentation, pathogenesis, and management strategies. Expert Opinion on Drug Safety 22:10, pages 921-928.
Read now
Read now
Yan-Li Hou, Di-Ya Wang, Jie-Xuan Hu, Ru-Yue Tian, Wei Wang, Qiang Su, Hongyang Li & Yan-Ling Wang. (2022) Risk of Ophthalmic Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis. Ocular Immunology and Inflammation 30:6, pages 1449-1459.
Read now
Read now
Eliot R. Dow, Kirk Hou, Susan Ransome, Sam Abbassi & Edmund Tsui. (2022) Posterior Uveitis Associated with Cemiplimab. Ocular Immunology and Inflammation 30:5, pages 1211-1213.
Read now
Read now
David Bomze, Tomer Meirson, Omar Hasan Ali, Adam Goldman, Lukas Flatz & Zohar Habot-Wilner. (2022) Ocular Adverse Events Induced by Immune Checkpoint Inhibitors: A Comprehensive Pharmacovigilance Analysis. Ocular Immunology and Inflammation 30:1, pages 191-197.
Read now
Read now
Edward J. Wladis & Madhavi L. Kambam. (2022) Ophthalmic complications of immune checkpoint inhibitors. Orbit 41:1, pages 28-33.
Read now
Read now
Ozgen Ahmet Yildirim, Kerem Poyraz, Erkan Erdur, Canan Can, Cihan Gundogan, Yunus Guzel, Hülya Etem & Halil Kömek. (2021) Nivolumab-Related Dry Mouth and Dry Eye: Cross-Sectional Study. Cancer Investigation 39:10, pages 797-807.
Read now
Read now
Ruby A. Parikh, Benjamin C. Chaon & Meghan K. Berkenstock. (2021) Ocular Complications of Checkpoint Inhibitors and Immunotherapeutic Agents: A Case Series. Ocular Immunology and Inflammation 29:7-8, pages 1585-1590.
Read now
Read now
Pol Specenier. (2021) Cost-effectiveness of nivolumab in advanced melanoma: a drug review. Expert Review of Pharmacoeconomics & Outcomes Research 21:1, pages 13-28.
Read now
Read now
Junwon Lee, Joo Youn Shin, Jihei Sara Lee, Sung Chul Lee, Min Hee Hong & Christopher Seungkyu Lee. (2020) Recurrent Sympathetic Ophthalmia with Annular Choroidal Detachment after Pembrolizumab Treatment: A Case Report. Ocular Immunology and Inflammation 28:6, pages 864-867.
Read now
Read now
Carl W. Noble, Sapna S. Gangaputra, Ian A. Thompson, Amy Yuan, Andrea B. Apolo, Jung-Min Lee, George N. Papaliodis, Shilpa Kodati, Rachel Bishop, M. Teresa Magone, Lucia Sobrin & H. Nida Sen. (2020) Ocular Adverse Events following Use of Immune Checkpoint Inhibitors for Metastatic Malignancies. Ocular Immunology and Inflammation 28:6, pages 854-859.
Read now
Read now
Chang‐chi Weng, Chih‐chiau Wu & Pei‐yu Lin. (2020) Corneal melting in a case undergoing treatment with pembrolizumab. Clinical and Experimental Optometry 103:3, pages 379-381.
Read now
Read now
Michel M. Sun$suffix/text()$suffix/text(), Ralph D. Levinson$suffix/text()$suffix/text(), Artur Filipowicz$suffix/text()$suffix/text(), Stephen Anesi$suffix/text()$suffix/text(), Henry J. Kaplan$suffix/text()$suffix/text(), Wei Wang$suffix/text()$suffix/text(), Debra A. Goldstein$suffix/text()$suffix/text(), Sapna Gangaputra$suffix/text()$suffix/text(), Robert T. Swan$suffix/text()$suffix/text(), H. Nida Sen$suffix/text()$suffix/text() & Lynn K. Gordon$suffix/text()$suffix/text(). (2020) Uveitis in Patients Treated with CTLA-4 and PD-1 Checkpoint Blockade Inhibition. Ocular Immunology and Inflammation 28:2, pages 217-227.
Read now
Read now
Articles from other publishers (93)
Ikuyo Sada, Yosuke Harada, Tomona Hiyama, Mina Mizukami, Takanobu Kan, Mikio Kawai & Yoshiaki Kiuchi. (2023) Uveitis associated with immune checkpoint inhibitors or BRAF/MEK inhibitors in patients with malignant melanoma. Melanoma Research 33:6, pages 539-546.
Crossref
Crossref
H. Fernández Jiménez-Ortiz, B. Maroto Rodríguez, R. Lapuente Monjas, R. Sampedro Yáñez, I. Sánchez Santos & N. Toledano Fernández. (2023) Iatrogenic affectation of ocular motility by immune checkpoint inhibitors. Archivos de la Sociedad Española de Oftalmología (English Edition).
Crossref
Crossref
Masaki Takeuchi, Akira Meguro, Jutaro Nakamura, Rei Chikagawa, Raiga Osada, Etsuko Shibuya, Yukiko Hasumi, Norihiro Yamada, Mami Ishihara & Nobuhisa Mizuki. (2023) HLA-DRB1*04:05 is involved in the development of Vogt–Koyanagi–Harada disease-like immune-related adverse events in patients receiving immune checkpoint inhibitors. Scientific Reports 13:1.
Crossref
Crossref
Xiangyi Kong, Li Chen, Zhaohui Su, Ryan J. Sullivan, Steven M. Blum, Zhihong Qi, Yulu Liu, Yujia Huo, Yi Fang, Lin Zhang, Jidong Gao & Jing Wang. (2023) Toxicities associated with immune checkpoint inhibitors: a systematic study. International Journal of Surgery 109:6, pages 1753-1768.
Crossref
Crossref
Pauline Casselman, Julie Jacob & Pieter-Paul Schauwvlieghe. (2023) Relation between ocular paraneoplastic syndromes and Immune Checkpoint Inhibitors (ICI): review of literature. Journal of Ophthalmic Inflammation and Infection 13:1.
Crossref
Crossref
A. Martens, P. P. Schauwvlieghe, A. Madoe, I. Casteels & S. Aspeslagh. (2023) Ocular adverse events associated with immune checkpoint inhibitors, a scoping review. Journal of Ophthalmic Inflammation and Infection 13:1.
Crossref
Crossref
Wan-Hua Cho & Wei-Yu Chiang. (2023) Case Report: Serial changes of ocular complications related to immune checkpoint inhibitors pembrolizumab and nivolumab. Frontiers in Ophthalmology 2.
Crossref
Crossref
Xavier L. Baldwin, Philip M. Spanheimer & Stephanie Downs-Canner. (2023) A Review of Immune Checkpoint Blockade for the General Surgeon. Journal of Surgical Research 281, pages 289-298.
Crossref
Crossref
Julia Aschauer, Ruth Donner, Jan Lammer & Gerald Schmidinger. (2022) Bilateral corneal perforation in Ipilimumab/Nivolumab - associated peripheral ulcerative keratitis. American Journal of Ophthalmology Case Reports 28, pages 101686.
Crossref
Crossref
Anam A. Mazharuddin, Andrew T. Whyte, Dan S. Gombos, Nimisha Patel, Azadeh Razmandi, Amina L. Chaudhry & Nagham S. Al-Zubidi. (2022) Highlights on Ocular Toxicity of Immune Checkpoint Inhibitors at a US Tertiary Cancer Center. Journal of Immunotherapy and Precision Oncology 5:4, pages 98-104.
Crossref
Crossref
André Borges Silva, João Figueira & Cristina Fonseca. (2022) A Pigmented Epiretinal Membrane in the Eighth Decade of Life. JAMA Ophthalmology 140:11, pages 1135.
Crossref
Crossref
Kayoko Ikegawa, Shintaro Kanda, Mitsuyo Okada, Takaomi Hanaoka, Makoto Kurai & Tomonobu Koizumi. (2022) Acute Sialadenitis Induced by Pembrolizumab in a Patient with Non-small Cell Lung Cancerペムブロリズマブによる急性唾液腺炎をきたした進行非小細胞肺癌の1例. Haigan 62:5, pages 433-437.
Crossref
Crossref
Charles B. Nguyen, Christopher T. Su, Meredith Morgan & Ajjai S. Alva. (2022) Case report: Immune-mediated meibomian gland dysfunction following pembrolizumab therapy for advanced urothelial carcinoma. Frontiers in Oncology 12.
Crossref
Crossref
Víctor Albarrán-Artahona, Juan-Carlos Laguna, Teresa Gorría, Javier Torres-Jiménez, Mariona Pascal & Laura Mezquita. (2022) Immune-Related Uncommon Adverse Events in Patients with Cancer Treated with Immunotherapy. Diagnostics 12:9, pages 2091.
Crossref
Crossref
Dexin Jiang, Yidan Lyu, Rui Miao & Ruoyun Wang. (2022) Toxicities of Pembrolizumab in Cancer Patients. Highlights in Science, Engineering and Technology 6, pages 284-291.
Crossref
Crossref
R.E. O'Cearbhaill, L. Clark, R.N. Eskander, S. Gaillard, J. Moroney, E. Pereira & B. Pothuri. (2022) Immunotherapy toxicities: An SGO clinical practice statement. Gynecologic Oncology 166:1, pages 25-35.
Crossref
Crossref
Julia Aschauer, Ruth Donner, Jan Lammer & Gerald Schmidinger. (2022) Atezolizumab induced immune-related adverse event mimicking conjunctival metastatic disease. American Journal of Ophthalmology Case Reports 26, pages 101489.
Crossref
Crossref
Justus G. Garweg. (2022) Uveitisinduktion durch immunonkologische Therapien, speziell Checkpoint-Inhibitoren. Klinische Monatsblätter für Augenheilkunde 239:04, pages 575-581.
Crossref
Crossref
Raju Vaddepally, Rajiv Doddamani, Soujanya Sodavarapu, Narasa Raju Madam, Rujuta Katkar, Anupama P. Kutadi, Nibu Mathew, Rohan Garje & Abhinav B. Chandra. (2022) Review of Immune-Related Adverse Events (irAEs) in Non-Small-Cell Lung Cancer (NSCLC)—Their Incidence, Management, Multiorgan irAEs, and Rechallenge. Biomedicines 10:4, pages 790.
Crossref
Crossref
Ioana Claudia Popteanu, Marian Burcea & Alexandru Grigorescu. (2022) Toxicitatea oculară a terapiilor biologice în tumorile solide. Oncolog-Hematolog.ro 4:61, pages 40.
Crossref
Crossref
Supriya Arora, Thamolwan Surakiatchanukul, Tarun Arora, Marie Helene Errera, Hitesh Agrawal, Marco Lupidi & Jay Chhablani. (2022) Retinal toxicities of systemic anticancer drugs. Survey of Ophthalmology 67:1, pages 97-148.
Crossref
Crossref
Anam Mazharuddin, Dan S. Gombos & Nagham Al-Zubidi. 2022. Global Perspectives in Ocular Oncology. Global Perspectives in Ocular Oncology
337
347
.
Subahari Raviskanthan, Melissa M. Chu, Peter W. Mortensen, Andrew G. Lee & Nagham Al-Zubidi. 2022. Managing Immunotherapy Related Organ Toxicities. Managing Immunotherapy Related Organ Toxicities
231
253
.
Christine Fardeau, Mehdi Bencheqroun, Arielle Levy, Sophie Bonnin, Marie-Adélaïde Ferchaud, Leila Fardeau, Florence Coscas, Bahram Bodaghi & Bénédicte Lebrun-Vignes. (2021) Uveitis associated with cancer immunotherapy: long-term outcomes. Immunotherapy 13:18, pages 1465-1481.
Crossref
Crossref
Pan Shen, Xuan Deng, Zhishuo Hu, Zhe Chen, Yao Huang, Ke Wang, Kai Qin, Ying Huang, Xin Ba, Jiahui Yan, Liang Han & Shenghao Tu. (2021) Rheumatic Manifestations and Diseases From Immune Checkpoint Inhibitors in Cancer Immunotherapy. Frontiers in Medicine 8.
Crossref
Crossref
Carmen Alba-Linero & Emilio Alba. (2021) Ocular side effects of checkpoint inhibitors. Survey of Ophthalmology 66:6, pages 951-959.
Crossref
Crossref
Kevin F. ElwoodJose S. Pulido, Shelley Day GhafooriC. Armitage HarperRobert W. Wong. (2021) CHOROIDAL NEOVASCULARIZATION AND CHORIORETINAL ATROPHY IN A PATIENT WITH MELANOMA-ASSOCIATED RETINOPATHY AFTER IPILIMUMAB/NIVOLUMAB COMBINATION THERAPY. RETINAL Cases & Brief Reports 15:5, pages 514-518.
Crossref
Crossref
Maram E.A. Abdalla Elsayed & Igor Kozak. (2021) Pharmacologically induced uveitis. Survey of Ophthalmology 66:5, pages 781-801.
Crossref
Crossref
Jade L Hefler, Lauren M Bailey, Cynthia El Rahi, Amy C Schefler & Eric H Bernicker. (2020) Panuveitis in patient on ipilimumab/nivolumab combination for small-cell lung cancer treated with an intravitreal dexamethasone implant. Journal of Oncology Pharmacy Practice 27:5, pages 1261-1264.
Crossref
Crossref
LeAnne Young, Shanda Finnigan, Howard Streicher, Helen X Chen, James Murray, H Nida Sen & Elad Sharon. (2021) Ocular adverse events in PD-1 and PD-L1 inhibitors. Journal for ImmunoTherapy of Cancer 9:7, pages e002119.
Crossref
Crossref
Julie R Brahmer, Hamzah Abu-Sbeih, Paolo Antonio Ascierto, Jill Brufsky, Laura C Cappelli, Frank B Cortazar, David E Gerber, Lamya Hamad, Eric Hansen, Douglas B Johnson, Mario E Lacouture, Gregory A Masters, Jarushka Naidoo, Michele Nanni, Miguel-Angel Perales, Igor Puzanov, Bianca D Santomasso, Satish P Shanbhag, Rajeev Sharma, Dimitra Skondra, Jeffrey A Sosman, Michelle Turner & Marc S Ernstoff. (2021) Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. Journal for ImmunoTherapy of Cancer 9:6, pages e002435.
Crossref
Crossref
Kyung Woo Kim, Sentaro Kusuhara, Motoko Tachihara, Chihiro Mimura, Wataru Matsumiya & Makoto Nakamura. (2021) A case of panuveitis and retinal vasculitis associated with pembrolizumab therapy for metastatic lung cancer. American Journal of Ophthalmology Case Reports 22, pages 101072.
Crossref
Crossref
Blake H. Fortes, Prashant D. Tailor & Lauren A. Dalvin. (2021) Ocular Toxicity of Targeted Anticancer Agents. Drugs 81:7, pages 771-823.
Crossref
Crossref
Royce B. Park, Sandeep Jain, Hui Han & Jennifer Park. (2021) Ocular surface disease associated with immune checkpoint inhibitor therapy. The Ocular Surface 20, pages 115-129.
Crossref
Crossref
David Braun, Darios Getahun, Vicki Y. Chiu, Anne L. Coleman, Gary N. Holland, Fei Yu, Lynn K. Gordon & Michel M. Sun. (2021) Population-Based Frequency of Ophthalmic Adverse Events in Melanoma, Other Cancers, and After Immune Checkpoint Inhibitor Treatment. American Journal of Ophthalmology 224, pages 282-291.
Crossref
Crossref
Charlene Y. C. Chau, Kendrick C. Shih, Loraine L. W. Chow & Victor H. F. Lee. (2020) Considerations for Use of Immune Checkpoint Inhibitors in Cancer Therapy for Patients with Co-Existing Thyroid Eye Disease. Ophthalmology and Therapy 10:1, pages 5-12.
Crossref
Crossref
Shruthi Harish Bindiganavile, Nita Bhat, Andrew G. Lee, Dan S. Gombos & Nagham Al-Zubidi. (2021) Targeted Cancer Therapy and Its Ophthalmic Side Effects: A Review. Journal of Immunotherapy and Precision Oncology 4:1, pages 6-15.
Crossref
Crossref
Paola Maria Cutroneo, Valentina Isgrò, Valentina Ientile, Mariacarmela Santarpia, Guido Ferlazzo, Andrea Fontana, Paolo Carrega, Elena Matarangolo, Simona Barnaba, Edoardo Spina & Gianluca Trifirò. (2020) Safety profile of immune checkpoint inhibitors: An analysis of the Italian spontaneous reporting system database. British Journal of Clinical Pharmacology 87:2, pages 527-541.
Crossref
Crossref
Anaïs Ramaekers, Sandrine Aspeslagh, Nele De Brucker, Camille Van MierloMarcel ten Tusscher, Pieter-Paul SchauwvliegheKarolien Termote. (2021) Bilateral Corneal Perforation in a Patient Under Anti-PD1 Therapy. Cornea 40:2, pages 245-247.
Crossref
Crossref
Florentia Dimitriou, Ursula Urner-Bloch, Corinne Eggenschwiler, Nicholas Mitsakakis, Joanna Mangana, Reinhard Dummer & Martin Urner. (2021) The association between immune checkpoint or BRAF/MEK inhibitor therapy and uveitis in patients with advanced cutaneous melanoma. European Journal of Cancer 144, pages 215-223.
Crossref
Crossref
Mattia Brigida, Alessia Perricelli, Fausto Sposato, Maria Giovanna Spadafora, Angelo Pomillo & Milito Sisto. (2021) Management of Immunotherapy Adverse Events in Oncological Patients: Anti-CTLA-4, Anti-PD-1/PD-L1. Reviews on Recent Clinical Trials 15:4, pages 339-346.
Crossref
Crossref
Vicktoria Vishnevskia-Dai, Lihi Rozner, Raanan Berger, Ziv Jaron, Sivan Elyashiv, Gal Markel & Ofira Zloto. (2021) Ocular side effects of novel anti-cancer biological therapies. Scientific Reports 11:1.
Crossref
Crossref
Nagham Al-Zubidi, J. Cody Page, Dan S. Gombos, Akanksha Srivastava, Eric Appelbaum, Paul W. Gidley, Mark S. Chambers & Marc-Elie Nader. 2021. Immunotherapy. Immunotherapy
399
416
.
Marianne Davies & Armand Russo. 2021. Lung Cancer. Lung Cancer
139
173
.
Blake M. Warner & Alan N. Baer. 2021. Rheumatic Diseases and Syndromes Induced by Cancer Immunotherapy. Rheumatic Diseases and Syndromes Induced by Cancer Immunotherapy
109
142
.
Ramsudha Narala, Sunil A. Reddy & Prithvi Mruthyunjaya. (2020) “Giant cell arteritis manifesting as retinal arterial occlusion and paracentral acute middle maculopathy in a patient on pembrolizumab for metastatic uveal melanoma”. American Journal of Ophthalmology Case Reports 20, pages 100891.
Crossref
Crossref
Sai‐Ching Jim Yeung, Aiham Qdaisat, Patrick Chaftari, Demis Lipe, Jeffrey Merlin, Eva Rajha, Adriana Wechsler, Marcelo Sandoval, Jayne Viets, Aisha Al‐Breiki, Mohsin Shah, Ramesh Pandey, Mona Kamal, Osama Khattab, Katy Toale, Monica Wattana, Ahmed Elsayem, Susan Gaeta, Patricia Brock, Cielito Reyes‐Gibby & Kumar Alagappan. (2020) Diagnosis and management of immune‐related adverse effects of immune checkpoint therapy in the emergency department. Journal of the American College of Emergency Physicians Open 1:6, pages 1637-1659.
Crossref
Crossref
Jessica C. Lee, Ghadeer Al-Humimat & Karanjit S. Kooner. (2020) Acute Bilateral Uveitis, Hypotony, and Cataracts Associated with Ipilimumab and Nivolumab Therapy: Optical Coherence Tomography Angiography Findings. Case Reports in Ophthalmology 11:3, pages 606-611.
Crossref
Crossref
Ling Peng, Qi-Qi Mao, Bo Jiang, Jin Zhang, Yi-Lei Zhao, Xiao-Dong Teng, Jin-Song Yang, Yang Xia, Shi-Qing Chen, Justin Stebbing & Hai Jiang. (2020) Bilateral Posterior Uveitis and Retinal Detachment During Immunotherapy: A Case Report and Literature Review. Frontiers in Oncology 10.
Crossref
Crossref
Shiori Hasegawa, Hiroaki Ikesue, Satoshi Nakao, Kazuyo Shimada, Ririka Mukai, Mizuki Tanaka, Kiyoka Matsumoto, Misaki Inoue, Riko Satake, Yu Yoshida, Fumiya Goto, Tohru Hashida & Mitsuhiro Nakamura. (2020) Analysis of immune‐related adverse events caused by immune checkpoint inhibitors using the Japanese Adverse Drug Event Report database. Pharmacoepidemiology and Drug Safety 29:10, pages 1279-1294.
Crossref
Crossref
Heba T. Rihani & Wendy M. Smith. (2020) Drug-Induced Uveitis: Part 1. Advances in Ophthalmology and Optometry 5, pages 265-306.
Crossref
Crossref
Uma Thanarajasingam & Noha Abdel-Wahab. (2020) Immune Checkpoint Inhibition—Does It Cause Rheumatic Diseases? Mechanisms of Cancer-Associated Loss of Tolerance and Pathogenesis of Autoimmunity. Rheumatic Disease Clinics of North America 46:3, pages 587-603.
Crossref
Crossref
Katharina C. Kähler, Jessica C. Hassel, Lucie Heinzerling, Carmen Loquai, Kai‐Martin Thoms, Selma Ugurel, Lisa Zimmer & Ralf Gutzmer. (2020) Nebenwirkungsmanagement bei Immun‐Checkpoint‐Blockade durch CTLA‐4‐ und PD‐1‐Antikörper beim metastasierten Melanom – ein Update. JDDG: Journal der Deutschen Dermatologischen Gesellschaft 18:6, pages 582-609.
Crossref
Crossref
Katharina C. Kähler, Jessica C. Hassel, Lucie Heinzerling, Carmen Loquai, Kai‐Martin Thoms, Selma Ugurel, Lisa Zimmer & Ralf Gutzmer. (2020) Side effect management during immune checkpoint blockade using CTLA‐4 and PD‐1 antibodies for metastatic melanoma – an update. JDDG: Journal der Deutschen Dermatologischen Gesellschaft 18:6, pages 582-609.
Crossref
Crossref
Mitchell S von Itzstein, Shaheen Khan & David E Gerber. (2020) Investigational Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Event Prediction and Diagnosis. Clinical Chemistry 66:6, pages 779-793.
Crossref
Crossref
Cindy Ung & Evangelos Gragoudas. (2020) Checkpoint inhibitor-induced sarcoid choroidal granulomas. American Journal of Ophthalmology Case Reports 18, pages 100652.
Crossref
Crossref
Jeanne de La Rochefoucauld, Nicolas Noël & Olivier Lambotte. (2020) Management of immune-related adverse events associated with immune checkpoint inhibitors in cancer patients: a patient-centred approach. Internal and Emergency Medicine 15:4, pages 587-598.
Crossref
Crossref
Konstantinos Melissaropoulos, Kalliopi Klavdianou, Alexandra Filippopoulou, Fotini Kalofonou, Haralabos Kalofonos & Dimitrios Daoussis. (2020) Rheumatic Manifestations in Patients Treated with Immune Checkpoint Inhibitors. International Journal of Molecular Sciences 21:9, pages 3389.
Crossref
Crossref
Yuri Kurono, Takayuki Takeda, Yusuke Kunimatsu, Nozomi Tani, Izumi Hashimoto & Kazuki Hirose. (2020) Vogt–Koyanagi–Harada disease during chemoimmunotherapy for non‐small cell lung cancer. Respirology Case Reports 8:3.
Crossref
Crossref
Xiaowei Liu, Zheng Wang, Chan Zhao, Hanping Wang, Xiaoxiao Guo, Jiaxin Zhou, Lian Duan, Xiaoyan Si, Li Zhang, Yue Li, Mengzhao Wang, Meifen Zhang & Li Zhang. (2020) Clinical diagnosis and treatment recommendations for ocular toxicities of targeted therapy and immune checkpoint inhibitor therapy. Thoracic Cancer 11:3, pages 810-818.
Crossref
Crossref
Juwhan Choi & Sung Yong Lee. (2020) Clinical Characteristics and Treatment of Immune-Related Adverse Events of Immune Checkpoint Inhibitors. Immune Network 20:1.
Crossref
Crossref
Sara R. Schoenfeld, Mary E. Aronow, Rebecca Karp Leaf, Michael Dougan & Kerry L. Reynolds. (2020) Diagnosis and Management of Rare Immune-Related Adverse Events. The Oncologist 25:1, pages 6-14.
Crossref
Crossref
Nicolas Feltgen. (2020) Retinale Komplikationen im Rahmen einer Tumortherapie mit Checkpoint-Inhibitoren. Kompass Ophthalmologie 6:3, pages 129-130.
Crossref
Crossref
C. Vidal Lopez, G.L. Ríos Quito, C. Salom Garrigues & A.I. Pellicer Sanahuja. (2020) Efectos adversos de la inmunoterapia oncohematológica: implicaciones para la Atención Primaria y la continuidad asistencial. Medicina de Familia. SEMERGEN 46:1, pages 60-67.
Crossref
Crossref
Akanksha Srivastava, Nagham Al-Zubidi, Eric Appelbaum, Dan S. Gombos, Marc-Elie Nader, Paul W. Gidley & Mark S. Chambers. 2020. Immunotherapy. Immunotherapy
295
307
.
Bertil Damato. 2020. Current Concepts in Ophthalmology. Current Concepts in Ophthalmology
275
293
.
Ester Simeone, Antonio M Grimaldi, Lucia Festino, Claudia Trojaniello, Maria G Vitale, Vito Vanella, Marco Palla & Paolo A Ascierto. (2019) Immunotherapy in metastatic melanoma: a novel scenario of new toxicities and their management. Melanoma Management 6:4, pages MMT30.
Crossref
Crossref
Giulia Corradetti, Sara Violanti, Adrian Au & David Sarraf. (2019) Wide field retinal imaging and the detection of drug associated retinal toxicity. International Journal of Retina and Vitreous 5:S1.
Crossref
Crossref
Joanna Mangana, Florentia Dimitriou, Ralph Braun, Sabine Ludwig, Reinhard Dummer & Marjam J. Barysch. (2019) Single-center real-life experience with low-dose ipilimumab monotherapy in adjuvant setting for patients with stage III melanoma. Melanoma Research 29:6, pages 648-654.
Crossref
Crossref
Noha Abdel-Wahab & Maria E Suarez-Almazor. (2019) Frequency and distribution of various rheumatic disorders associated with checkpoint inhibitor therapy. Rheumatology 58:Supplement_7, pages vii40-vii48.
Crossref
Crossref
Marianne Davies. (2019) Acute and Long-term Adverse Events Associated With Checkpoint Blockade. Seminars in Oncology Nursing 35:5, pages 150926.
Crossref
Crossref
Justus G. Garweg. (2019) Grundzüge der medikamentösen Therapie und chirurgische Optionen bei UveitisPharmacological treatment strategies and surgical options for uveitis. Der Ophthalmologe 116:10, pages 942-950.
Crossref
Crossref
Mike Nguyen, Md Rafiqul Islam, Shueh Wen Lim, Arvind Sahu & Babak Tamjid. (2019) Pembrolizumab Induced Ocular Hypotony With Near Complete Vision Loss, Interstitial Pulmonary Fibrosis and Arthritis. Frontiers in Oncology 9.
Crossref
Crossref
Omar Abdel-Rahman & Zeinab Elsayed. (2019) Immune checkpoint inhibitors for unresectable hepatocellular carcinoma. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Filipe Martins, Latifyan Sofiya, Gerasimos P. Sykiotis, Faiza Lamine, Michel Maillard, Montserrat Fraga, Keyvan Shabafrouz, Camillo Ribi, Anne Cairoli, Yan Guex-Crosier, Thierry Kuntzer, Olivier Michielin, Solange Peters, Georges Coukos, Francois Spertini, John A. Thompson & Michel Obeid. (2019) Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nature Reviews Clinical Oncology 16:9, pages 563-580.
Crossref
Crossref
Christina Rodriguez, Rebecca Sieburth, Steven Newman, Elizabeth Gaughan & Yevgeniy (Eugene) Shildkrot. (2019) Bilateral Mydriasis and Serous Retinal Detachments Associated With Ipilimumab and 6-Melanoma Helper Peptide Vaccine for Cutaneous Melanoma. JAMA Ophthalmology 137:9, pages 1088.
Crossref
Crossref
Xerxes N Pundole, Mayur Sarangdhar & Maria E Suarez-Almazor. (2019) Rheumatic and Musculoskeletal Adverse Events with Immune Checkpoint Inhibitors: Data from the United States Food and Drug Administration Adverse Event Reporting System. Journal of Immunotherapy and Precision Oncology 2:3, pages 65-73.
Crossref
Crossref
Caoilfhionn Connolly, Kalindi Bambhania & Jarushka Naidoo. (2019) Immune-Related Adverse Events: A Case-Based Approach. Frontiers in Oncology 9.
Crossref
Crossref
Karen Bitton, Jean-Marie Michot, Emmanuel Barreau, Olivier Lambotte, Oscar Haigh, Aurélien Marabelle, Anne-Laure Voisin, Christine Mateus, Anne-Laure Rémond, Chloé Couret, Stéphane Champiat, Marc Labetoulle & Antoine Rousseau. (2019) Prevalence and Clinical Patterns of Ocular Complications Associated With Anti-PD-1/PD-L1 Anticancer Immunotherapy. American Journal of Ophthalmology 202, pages 109-117.
Crossref
Crossref
Omar Abdel-Rahman. (2019) Toxicity patterns associated with chemotherapy/immune checkpoint inhibitor combinations: a meta-analysis. Immunotherapy 11:6, pages 543-554.
Crossref
Crossref
John A. ThompsonBryan J. SchneiderJulie BrahmerStephanie AndrewsPhilippe ArmandShailender BhatiaLihua E. BuddeLuciano CostaMarianne DaviesDavid DunningtonMarc S. ErnstoffMatthew FrigaultBrianna HoffnerChristopher J. HoimesMario LacoutureFrederick LockeMatthew LunningNisha A. MohindraJarushka NaidooAnthony J. OlszanskiOlalekan OluwoleSandip P. PatelSunil ReddyMabel RyderBianca SantomassoScott ShoferJeffrey A. SosmanMomen WahidiYinghong Wang, Alyse Johnson-ChillaJillian L. Scavone. (2019) Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network 17:3, pages 255-289.
Crossref
Crossref
Huan-huan Ji, Xue-wen Tang, Zhi Dong, Lin Song & Yun-tao Jia. (2019) Adverse Event Profiles of Anti-CTLA-4 and Anti-PD-1 Monoclonal Antibodies Alone or in Combination: Analysis of Spontaneous Reports Submitted to FAERS. Clinical Drug Investigation 39:3, pages 319-330.
Crossref
Crossref
Wei Wang, Wai-Ching Lam & Ling Chen. (2018) Recurrent grade 4 panuveitis with serous retinal detachment related to nivolumab treatment in a patient with metastatic renal cell carcinoma. Cancer Immunology, Immunotherapy 68:1, pages 85-95.
Crossref
Crossref
Leisha A. Emens, S. Lindsey Davis, Scott C. N. Oliver, Christopher H. Lieu, Ashvini Reddy, Sharon Solomon, Lingmin He, Roland Morley, Marcella Fassò, Andrea Pirzkall, Hina Patel, Carol O’Hear & Daniela Ferrara. (2019) Association of Cancer Immunotherapy With Acute Macular Neuroretinopathy and Diffuse Retinal Venulitis. JAMA Ophthalmology 137:1, pages 96.
Crossref
Crossref
Tomoki Tamura, Etsuko Akimoto, Chiaki Matsumoto, Syunta Mori, Tatuya Nishi, Kennichiro Kudo & Syouichi Kuyama. (2018) Vogt-Koyanagi-Harada Syndrome Induced by Pembrolizumab in a Patient with Non–Small Cell Lung Cancer. Journal of Thoracic Oncology 13:10, pages 1606-1607.
Crossref
Crossref
Daniel J. Pallin, Christopher W. Baugh, Michael A. Postow, Jeffrey M. Caterino, Timothy B. Erickson & Gary H. Lyman. (2018) Immune‐related Adverse Events in Cancer Patients. Academic Emergency Medicine 25:7, pages 819-827.
Crossref
Crossref
Lauren A. Dalvin, Carol L. Shields, Marlana OrloffTakami SatoJerry A. Shields. (2018) CHECKPOINT INHIBITOR IMMUNE THERAPY. Retina 38:6, pages 1063-1078.
Crossref
Crossref
Lisa A. Kottschade. (2018) Incidence and Management of Immune-Related Adverse Events in Patients Undergoing Treatment with Immune Checkpoint Inhibitors. Current Oncology Reports 20:3.
Crossref
Crossref
Lisa Kottschade. 2018. The Basics of Cancer Immunotherapy. The Basics of Cancer Immunotherapy
143
152
.
D. Teyssonneau, S. Cousin & A. Italiano. (2017) Gougerot-Sjogren-like syndrome under PD-1 inhibitor treatment. Annals of Oncology 28:12, pages 3108.
Crossref
Crossref
Omar Abdel-Rahman, Mostafa Eltobgy, Hani Oweira, Anwar Giryes, Aysun Tekbas & Michael Decker. (2017) Immune-related musculoskeletal toxicities among cancer patients treated with immune checkpoint inhibitors: a systematic review. Immunotherapy 9:14, pages 1175-1183.
Crossref
Crossref
Hiroaki Kanno, Kyoko Ishida, Wataru Yamada, Takashi Nishida, Nobumichi Takahashi, Kiyofumi Mochizuki, Yuki Mizuno, Kanako Matsuyama, Tomoko Takahashi & Mariko Seishima. (2017) Uveitis induced by programmed cell death protein 1 inhibitor therapy with nivolumab in metastatic melanoma patient. Journal of Infection and Chemotherapy 23:11, pages 774-777.
Crossref
Crossref
Pui Ying Chan, Peter Hall, Gordon Hay, Victoria M. L. Cohen & Peter W. Szlosarek. (2017) A major responder to ipilimumab and nivolumab in metastatic uveal melanoma with concomitant autoimmunity. Pigment Cell & Melanoma Research 30:6, pages 558-562.
Crossref
Crossref